Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed May 7, 2015
Insider Transaction Report
Form 4
Palash Tzvi
Chief Operating Officer
Transactions
- Award
Stock Options (Right to Buy)
2015-03-23+125,000→ 125,000 totalExercise: $1.72Exp: 2025-03-23→ Common Stock (125,000 underlying)
Footnotes (2)
- [F1]25% of the shares of common stock underlying the stock options shall vest on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
- [F2]Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $7.55 per share that expire on August 29, 2020.